4157 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
TaiGen Biopharmaceuticals Holdings Ltd. engages in the development of novel therapeutics for infectious diseases, cancer, and diabetes-related complications. Its products include treatment fordrug-resistant bacterial infections Nemonoxacin, stem cell mobilizer Burixafor, anti-influenza drug TG-1000 and anti-hapatitis C virus drug Furaprevir. The company was founded on September 15, 2005 and is headquartered in Taipei, Taiwan.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
4157 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company